Fed. Circ. Won't Restore Merck's $2.5B Patent Win Over Gilead
The Federal Circuit on Wednesday upheld a lower court's decision to overturn a jury verdict requiring Gilead Sciences Inc. to pay Merck & Co.'s Idenix subsidiary more than $2.5 billion for...To view the full article, register now.
Already a subscriber? Click here to view full article